Fredun Pharma Confirms Fund Use, Agency Cites Data Delays

Fredun Pharmaceuticals has confirmed that its ₹107.78 crore raised through a preferential issue was used as planned up to March 31, 2026. The company's statement indicated no deviation in fund utilisation for the period. However, monitoring agency CARE Ratings noted that delays in receiving data from the company, due to internal system upgrades, limited its ability to comment on potential deviations.

The company submitted its fund utilisation statement for the quarter ending March 31, 2026, with Board approval. Fredun stated that unutilised funds remain invested in permitted instruments, aligning with the original fundraising objectives. The preferential issue was conducted on December 29, 2025, following Board approval on November 5, 2025, and the funds were earmarked for working capital needs and general corporate purposes.

CARE Ratings reported that it could not provide commentary on any deviations in fund utilisation because of the late submission of necessary data from Fredun Pharmaceuticals. These delays were attributed by the company to ongoing internal server and software upgrades. This situation highlights the importance of timely information flow for independent oversight.

Fredun Pharma operates in the competitive Indian pharmaceutical sector as a manufacturer of APIs and generic drugs. Competitors include Marksans Pharma Ltd. and Indoco Remedies Ltd., which also focus on APIs and generic formulations, often with significant export business. FDC Ltd. is another established player navigating both domestic and international markets.

Investors will be monitoring future disclosures for improved data submission timeliness. Tracking the ultimate deployment and impact of the funds on the company's operations, along with any further updates from CARE Ratings, will also be important.